Evidence map›Paper›PMID 40032983›Full record

ArticleScientific reports2025

MRI radiomics based on machine learning in high-grade gliomas as a promising tool for prediction of CD44 expression and overall survival.

Mingjun Yu, Jinliang Liu, Wen Zhou, Xiao Gu, Shijia Yu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mingjun YuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Jinliang LiuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Wen ZhouDepartment of Pain Management, Dalian Municipal Central Hospital, Dalian, 116033, People's Republic of China.
Xiao GuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. tulipbc@163.com.
Shijia YuDepartment of Neurology, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China. sjyu@cmu.edu.cn.

Funding

National Natural Science Foundation of China 82001475Support for the High-Quality Development of China Medical University Project of Liaoning Province 2023JH2/20200158Young Talents of Education Ministry of Liaoning Province QN2019016
6 · The paper itself

Abstract

We aimed to predict CD44 expression and assess its prognostic significance in patients with high-grade gliomas (HGG) using non-invasive radiomics models based on machine learning. Enhanced magnetic resonance imaging, along with the corresponding gene expression and clinicopathological data, was downloaded from online database. Kaplan-Meier survival curves, univariate and multivariate COX analyses, and time-dependent receiver operating characteristic were used to assess the prognostic value of CD44. Following the screening of radiomic features using repeat least absolute shrinkage and selection operator, two radiomics models were constructed utilizing logistic regression and support vector machine for validation purposes. The results indicated that CD44 protein levels were higher in HGG compared to normal brain tissues, and CD44 expression emerged as an independent biomarker of diminished overall survival (OS) in patients with HGG. Moreover, two predictive models based on seven radiomic features were built to predict CD44 expression levels in HGG, achieving areas under the curves (AUC) of 0.809 and 0.806, respectively. Calibration and decision curve analysis validated the fitness of the models. Notably, patients with high radiomic scores presented worse OS (p < 0.001). In summary, our results indicated that the radiomics models effectively differentiate CD44 expression level and OS in patients with HGG.

Indexed as

Brain NeoplasmsGliomaHyaluronan ReceptorsMachine LearningMagnetic Resonance ImagingAdultAgedBiomarkers, TumorFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm GradingPrognosisRadiomicsBiomarkers, TumorCD44 protein, humanHyaluronan ReceptorsCD44High-grade gliomaMachine learningOverall survivalRadiomics

Identifiers

PMID40032983
PMCPMC11876340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.